No Data
No Data
Synbio Pharmaceuticals Research Memo (12): Aiming to grow as a global specialty pharma as a long-term goal
■Future outlook 2. Long-term strategy Synbio Pharmaceuticals <4582> aims to grow as a global specialty pharma as a long-term goal, and wants to increase domestic and overseas sales ratios of 50%, respectively, by 2030. Domestically, in addition to “treaxine (R),” it is a strategy to expand sales by listing new items and BCVs to be introduced in the future, and to expand sales overseas by launching at least 2 items with BCV. As a BCV platform deployment
Synbio Pharmaceuticals Research Memo (10): Policy to secure cash on hand of 5.5 to 6.5 billion yen as a guide
■Performance Trends 2. Financial Status The total assets of Synbio Pharmaceuticals<4582> at the end of the 2023/12 fiscal year decreased 2,263 million yen from the end of the previous fiscal year to 8,170 million yen. Looking at the main factors of change, cash and deposits increased by 234 million yen in current assets, while accounts receivable decreased by 1,171 million yen. As for fixed assets, tangible fixed assets decreased by 69 million yen and software by 222 million yen, respectively, due to the recording of impairment losses, and deferred tax assets decreased by 744 million yen. What is the total debt
Synbio Pharmaceuticals Research Memo (9): Sales declined drastically in the 2023/12 fiscal year due to the penetration of generic drugs and falling drug prices
■Earnings Trends 1. Financial Overview for the Fiscal Year Ending 2023/12 The consolidated financial results for the fiscal year ending 2023/12 of Synbio Pharmaceuticals (4582) were sales down 44.1% from the previous fiscal year to 5,589 million yen, operating losses of 811 million yen (profit of 1,963 million yen in the previous fiscal year), ordinary losses of 736 million yen (same profit of 1,999 million yen), and net loss attributable to parent company shareholders was 1,962 million yen (profit of 1,179 million yen) for the first time in 4 periods, 3 The loss was recorded for the first time in the period. Sales are new models
Synbio Pharmaceuticals Research Memo (8): Rigocertib is exploring development possibilities in combination with other agents
■Other pipeline trends for Synbio Pharmaceuticals<4582> 2. “Ligosertib” (injection/oral agent) and “rigocertib” are anticancer drug candidates having a unique multi-kinase inhibitory effect (action that causes cancer cells to die by inhibiting multiple kinases involved in the proliferation, invasion, and metastasis of cancer cells). An international joint phase 3 clinical trial (INSPIRE trial) for myelodysplastic syndrome (MDS) was conducted at the introducer Onconova, 2020
Synbio Pharmaceuticals Research Memo (7): Market share of treaxine (R) is expected to decline moderately due to entry into generic pharmaceuticals
■Other pipeline trends for Synbio Pharmaceuticals<4582> 1. “Treaxine (R)” (generic name: bendamustine hydrochloride) and “treaxine (R)” are anticancer drugs for malignant lymphoma. Malignant lymphoma is a disease in which lymphocytes, which are a type of white blood cell, become cancerous (tumours) and form lumps (tumors) in lymph nodes and organs, and also occurs from lymph nodes distributed throughout the body and organs other than lymph nodes (stomach, intestines, thyroid, spinal cord, lungs, liver, skin, eyes, etc.). Of blood cancer
Synbio Pharmaceuticals Research Memo (4): BCV development risk reduction, aiming to obtain approval for 2 indications by 2030 (1)
■Synbio Pharmaceuticals<4582> BCV Development Strategy 2. The development pipeline BCV is currently being developed while conducting joint research with academia in multiple areas such as AdV infections, brain tumors, hematological tumors, and neurodegenerative diseases after hematopoietic stem cell transplantation. Of these, it was announced in 2023/5 that PoC was established in a phase 2 clinical trial targeting ADV infection after hematopoietic stem cell transplantation. Low development risk in other disease areas due to the establishment of POC
No Data